hVIVO PLC
HVO
Company Profile
Business description
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences’ Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.
Contact
42, New Road
Queen Mary Bioenterprises Innovation Centre
LondonE1 2AX
GBRE: info@venncro.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
274
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,524.30 | 323.30 | -4.12% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 8,049.07 | 5.91 | -0.07% |
| HKSE | 20,038.37 | 2,811.44 | -12.30% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,136.58 | 2,644.00 | -7.83% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,343.30 | 324.50 | -4.23% |
| SSE Composite Index | 3,107.30 | 234.71 | -7.02% |